Diagnos

Diagnos Net Margin

The Net Profit Margin of Diagnos (ADK.V) as of Nov 18, 2026 is -6,956.84 %. In the previous year, Net Profit Margin was -4,129.65 % — a change of 68.46% (lower).

Net Margin

-6,956.84 %

YoY

68.46%

Last updated:

Net Profit Margin of Diagnos is 2026 -6,956.84 % . Net Profit Margin of Diagnos was 2025 -4,129.65 % . It decreases by 68.46% lower compared to the previous year.

Diagnos's net margin stands at -6,956.8%, down from -594.4% several years earlier.

The Diagnos Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-1,175.93 CAD
Jan 1, 2020
-1,020.42 CAD
Jan 1, 2021
-768.07 CAD
Jan 1, 2022
-594.35 CAD
Jan 1, 2023
-510.72 CAD
Jan 1, 2024
-1,833.93 CAD
Jan 1, 2025
-4,129.65 CAD
Jan 1, 2026
-6,956.84 CAD
The Diagnos Net Margin history
YEARNet MarginYoY
-6,956.84 %+68.46%
-4,129.65 %+125.18%
-1,833.93 %+259.09%
-510.72 %-14.07%
-594.35 %-22.62%
-768.07 %-24.73%
-1,020.42 %-13.22%
-1,175.93 %+554.63%
-179.63 %-20.80%
-226.80 %-30.27%
-325.27 %-35.10%
-501.19 %+726.25%
-60.66 %+4,378.47%
-1.35 %-17.99%
-1.65 %+65.19%
-1.00 %-81.27%
-5.34 %+383.88%
-1.10 %+416.17%
-0.21 %-73.14%
-0.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diagnos Stock analysis

What does Diagnos do? Diagnos Inc. generates revenue through its AI-driven healthcare technical services, primarily via FLAIRE, which enables application modification and development. The company offers CARA, a tool using image enhancement algorithms for sharper retinal images, supporting real-time screening of large patient volumes. Its key markets include Canada, the United States, Saudi Arabia, Mexico, Costa Rica, and Chile, with subsidiaries Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited serving these regions. Clients are healthcare providers seeking advanced diagnostic tools for efficient patient screening. CARA’s real-time capabilities and image clarity make it a preferred solution for clinics and hospitals managing high patient throughput. FLAIRE’s application development features cater to healthcare institutions needing customized AI integrations. The company’s geographical reach spans multiple countries, leveraging its subsidiaries to serve diverse healthcare systems. Revenue streams are tied to software licensing and service contracts for these AI-powered diagnostic tools. Diagnos Inc. focuses on providing specialized AI tools for ophthalmology, with CARA being central to its offerings. The company’s subsidiaries facilitate localized market penetration, ensuring compliance and adaptation to regional healthcare needs. Clients include medical facilities requiring accurate and efficient diagnostic solutions, particularly in regions with growing healthcare infrastructure. Diagnos is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diagnos stock

Net Profit Margin of Diagnos is -6,956.84 % in 2026.

Net Profit Margin of Diagnos changed from -4,129.65 % to -6,956.84 %, representing a 68.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Diagnos since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Diagnos with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Diagnos

All Key Metrics — Diagnos